FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Continue Reading
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 28, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the... Continue Reading
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions Continue Reading
Advancing Prevention: ASPC Establishes Women’s Cardiovascular Health Working Group Continue Reading
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline Continue Reading
UC Irvine-led study of more than 220,000 U.S. adults links higher B vitamin levels with lower stroke risk Continue Reading
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research Continue Reading
American Society for Preventive Cardiology Announces 2026 Virtual Imaging Symposium Focused on Multimodality Cardiovascular Imaging for Prevention Continue Reading
New AJPC Study Examines How PREVENT Equations Translate Cardiovascular Risk Factors into Predicted CVD Risk Continue Reading
AJPC Publishes POLY-ACS Trial Demonstrating Feasibility of Polypill Strategy After Acute Coronary Syndrome Continue Reading
Chiesi Global Rare Diseases Announces FDA Approval of JUXTAPID® (lomitapide) Capsules for Pediatric Use in Homozygous Familial Hypercholesterolemia (HoFH) Continue Reading
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) Continue Reading
